<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.0 20120330//EN" "http://jats.nlm.nih.gov/publishing/1.0/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="1.0" xml:lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">SMF</journal-id>
      <journal-title-group>
        <journal-title>Schweizerisches Medizin-Forum</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1424-4020</issn>
      <issn pub-type="ppub">1424-3784</issn>
      <publisher>
        <publisher-name>EMH Schweizerischer Ärzteverlag AG</publisher-name>
        <publisher-loc>Farnsburgerstrasse 8
CH-4132 Muttenz</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">09158</article-id>
      <article-id pub-id-type="doi">10.4414/smf.2023.09158</article-id>
      <article-categories>
        <!-- rubric -->
        <subj-group subj-group-type="Article Type">
          <subject>Der besondere Fall</subject>
        </subj-group>
        <!-- topics -->
        <subj-group subj-group-type="Classification">
          <subject>Klinische Pharmakologie und Toxikologie</subject>
          <subject>Nephrologie</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Symptomatische Hypoglykämie und schwere akute Niereninsuffizienz unter Cotrimoxazol</article-title>
      </title-group>
      <contrib-group>
        <contrib id="author-1" contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Widmer</surname>
            <given-names>Valeria</given-names>
          </name>
          <email>valeria.widmer@gmx.ch</email>
          <aff>Rheinstrasse 26 | Liestal | 4410 | SWITZERLAND</aff>
        </contrib>
        <contrib id="author-2" contrib-type="author" corresp="no">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Späni</surname>
            <given-names>Selina</given-names>
          </name>
          <email/>
          <aff/>
        </contrib>
        <contrib id="author-3" contrib-type="author" corresp="no">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Zimmermanns</surname>
            <given-names>Barbara</given-names>
          </name>
          <email/>
          <aff>Universität Basel</aff>
        </contrib>
        <contrib id="author-4" contrib-type="author" corresp="no">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>von Stöckmann</surname>
            <given-names>Oliver</given-names>
          </name>
          <email/>
          <aff>Universitätsspital Basel</aff>
        </contrib>
        <contrib id="author-5" contrib-type="author" corresp="no">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Burkhalter</surname>
            <given-names>Felix</given-names>
          </name>
          <email/>
          <aff>SWITZERLAND</aff>
        </contrib>
        <contrib id="author-6" contrib-type="author" corresp="no">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Leuppi</surname>
            <given-names>Jörg</given-names>
          </name>
          <email/>
          <aff/>
        </contrib>
        <contrib id="author-7" contrib-type="author" corresp="no">
          <contrib-id contrib-id-type="orcid"/>
          <name>
            <surname>Leuppi-Taegtmeyer</surname>
            <given-names>Anne</given-names>
          </name>
          <email/>
          <aff/>
        </contrib>
      </contrib-group>
      <pub-date pub-type="epub" date-type="pub" iso-8601-date="2023.08.16">
        <day>16</day>
        <month>08</month>
        <year>2023</year>
      </pub-date>
      <volume>23</volume>
      <issue>33</issue>
      <fpage>1228</fpage>
      <lpage>1232</lpage>
      <permissions>
        <copyright-statement>Copyright: EMH Schweizerischer Ärzteverlag AG</copyright-statement>
        <copyright-year>2023</copyright-year>
        <copyright-holder>EMH Schweizerischer Ärzteverlag AG</copyright-holder>
        <license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
          <license-p>"Swiss Medical Forum" is an open access publication of EMH published in accordance with the terms of the Creative Commons licence attribution - NonCommercial - NoDerivatives 4.0 International. You are free to share, copy and redistribute the material in any medium or format under the following terms:</license-p>
          <license-p>Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.</license-p>
          <license-p>NonCommercial — You may not use the material for commercial purposes.</license-p>
          <license-p>NoDerivatives — If you remix, transform, or build upon the material, you may not distribute the modified material.</license-p>
          <license-p>"Non-commercial" means not primarily intended for or directed towards commercial advantage or monetary compensation. The incorporation of publications in commercial products, the use of publications to advertise for commercial products or services and any other usage that directly or indirectly pursues commercial interests is subject to the express previous consent of the publishing house as part of a written agreement.</license-p>
          <license-p>Please send us your request in writing. Exact indication of the publication from which you would like to reproduce material and detailed information about its intended use help to facilitate and expedite request processing.</license-p>
        </license>
      </permissions>
      <abstract abstract-type="article" xml:lang="de">
        <p>Fallbeschreibung einer 88-jährigen nicht diabetischen Patientin, die im Rahmen einer Steroidtherapie eine Pneumocystis jirovecci Pneumonie entwickelte. Unter der Hochdosis-Cotrimoxazol Therapie kam es zu einer symptomatischen Hypoglykämie, akuten Niereninsuffizienz und Dyselektrolytämie.
Die Sulfatgruppe von Sulfamethoxazol führt über einen ähnlichen Wirkmechanismus wie die Sulfonylharnstoffe zu einer Insulinausschüttung. Da Trimethoprim die Kreatininsekretion hemmt, kommt es immer zu einem Kreatininanstieg unter Cotrimoxazol. Eine bereits eingeschränkt Nierenfunktion kann den Effekt noch verstärken. Ausserdem hemmt Trimethoprim die Natrium-Kalium-ATPase, was zu Dyselektrolytämien führen kann.
Der zeitliche Ablauf der genannten Nebenwirkungen zeigt sich an unserem Fall exemplarisch mit Regredienz nach Stoppen von Cotrimoxazol.</p>
      </abstract>
    </article-meta>
  </front>
  <body/>
  <back/>
</article>
